Cholesterol lowering and coronary artery disease: Mechanisms of risk reduction

Heart

Volumn 80, Issue 6, 1998, Pages 543-547

  Archbold, R A ^a   Timmis, A D ^a  

^a LONDON CHEST HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; FIBRINOGEN; FLUINDOSTATIN; HIGH DENSITY LIPOPROTEIN; HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN; MATRIX METALLOPROTEINASE; MEVINOLIN; PRAVASTATIN; SIMVASTATIN; TISSUE INHIBITOR OF METALLOPROTEINASE;

ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR EFFECT; CELL PROLIFERATION; CHOLESTEROL METABOLISM; CORONARY ARTERY DISEASE; CORONARY RISK; DISEASE COURSE; FIBRINOGEN BLOOD LEVEL; HUMAN; LIPOPROTEIN METABOLISM; NONHUMAN; PRIORITY JOURNAL; REVIEW; RISK FACTOR; RISK MANAGEMENT; THROMBOCYTE ACTIVATION; VASCULAR ENDOTHELIUM; VASCULAR SMOOTH MUSCLE;

EID: 0031798297     PISSN: 13556037     EISSN: None     Source Type: Journal    
DOI: 10.1136/hrt.80.6.543     Document Type: Review

References (58)

1. Stamler J, Wentworth D, Neaton JD for the MRFIT Research Group. Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the multiple risk factor intervention trial (MRFIT). JAMA 1986;256:2823-8.
2. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandanavian simvastatin survival study (4S). Lancet 1994;344:1383-9.
3. Sacks FM, Pfeffer MA, Moye LA, et al for the Cholesterol and Recurrent Events Trial Investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996;335:1001-9.
4. Yla-Herttuala S, Palinski W, Rosenfeld ME, et al. Evidence for the presence of oxidatively modified low density lipoprotein in atherosclerotic lesions of rabbit and man. J Clin Invest 1989;84:1086-95.
5. Steinberg D, Parthasarathy S, Carew TE, et al. Beyond cholesterol: modifications of low-density-lipoprotein that increase its atherogenicity. N Engl J Med 1989;320-915-23.
6. Brown BG, Zhao X-Q, Sacco DE, et al. Lipid lowering and plaque regression. New insights into prevention of plaque disruption and clinical events in coronary disease. Circulation 1993;87:1781-91.
7. Vos J, de Feyter PJ, Simoons ML, et al. Retardation and arrest of progression or regression of coronary artery disease: a review. Prog Cardiovasc Dis 1993;35:435-54.
8. Ambrose J, Tannenbaum MA, Alexopoulos D, et al. Angiographic progression of coronary artery disease and the development of myocardial infarction. J Am Coll Cardiol 1988;12:56-62.
9. Little WC, Constantinescu M, Applegate RJ, et al. Can coronary angiography predict the site of a subsequent myocardial infarction in patients with mild-to-moderate coronary artery disease? Circulation 1988;78:1157-66.
10. Falk E. Plaque rupture with severe pre-existing stenosis precipitating coronary thrombosis: characteristics of coronary atherosclerotic plaques underlying fatal occlusive thrombi. Br Heart J 1983;50:127-34.
11. Davies MJ, Thomas AC. Plaque fissuring - the cause of acute myocardial infarction, sudden ischaemic death, and crescendo angina. Br Heart J 1985;53:363-73.
12. Davies MJ, Bland JM, Hangartner JRW, et al. Factors influencing the presence or absence of acute coronary artery thrombi in sudden ischaemic death. Eur Heart J 1989;10: 203-8.
13. Davies MJ. Stability and instability: two faces of coronary atherosclerosis. The Paul Dudley White Lecture 1995. Circulation 1996;94:2013-20.
14. Fuster V, Badimon L, Badimon JJ, et al. The pathogenesis of coronary artery disease and the acute coronary syndromes (first of two parts). N Engl Med 1992;326:242-50.
15. Richardson PD, Davies MJ, Born GVR. Influence of plaque configuration and stress distribution on fissuring of coronary atherosclerotic plaques. Lancet 1989;ii:941-4.
16. Lee RT, Kamm RD. Vascular mechanics for the cardiologist. J Am Coll Cardiol 1994;23:1289-95.
17. Davies MJ, Richardson PD, Woolf N, et al. Risk of thrombosis in human atherosclerotic plaques: role of extracellular lipid, macrophage, and smooth muscle content. Br Heart J 1993;69:377-81.
18. Libby P. Molecular bases of the acute coronary syndromes. Circulation 1995;91:2844-50.
19. Dollery CM, McEwan JR, Henney AM. Matrix metalloproteinases and cardiovascular disease. Circ Res 1995;77:863-8.
20. Galis ZS, Sukhova GK, Lark MW, et al. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest 1994;94:2493-2503.
21. van der Wal AC, Becker AE, van der Loos CM, et al. Site of intimai rupture or erosion of thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant plaque morphology. Circulation 1994;89:36-44.
22. Small DM, Bond MG, Waugh D, et al. Physiochemical and histological changes in the arterial wall of non-human primates during progression and regression of atherosclerosis. J Clin Invest 1984;73:1590-1605.
23. Harrison DG, Armstrong MT, Freiman PC, et al. Restoration of endothelial-dependent relaxation by dietary treatment of atherosclerosis. J Clin Invest 1987;80:1808-11.
24. Shiomi M, Ito T, Tsukada T, et al. Reduction of serum cholesterol levels alters lesional composition of atherosclerotic plaques. Effect of pravastatin sodium on atheroscerosis in mature WHHL rabbits. Arterioscler Thromb Biol 1995;15: 1938-44.
25. Aikawa M, Rabkin E, Okada Y, et al. Lipid lowering by diet reduces matrix metalloproteinase activity and increases collagen content of rabbit atheroma: a potential mechanism of lesion stabilisation. Circulation 1998;97:2433-44.
26. Celermajer DS. Endothelial dysfunction: does it matter? Is it reversible? J Am Coll Cardiol 1997;30:325-33.
27. Luscher TF, Barton M. Biology of the endothelium. Clin Cardiol 1997;20(suppl II):II3-10.
28. Furchgott RF, Zawadzki JV. The obligatory role of the endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 1980;288:373-6.
29. Freiman PC, Mitchell GG, Heistad DD, et al. Atherosclerosis impairs endothelium-dependent vascular relaxation to acetylcholine and thrombin in primates. Circ Res 1986;58: 783-9.
30. Chappell SP, Lewis MJ, Henderson AH. Effect of lipid lowering on endothelium dependent relaxation in rabbit aortic preparations. Cardiovasc Res 1987;21:34-8.
31. Ludmer PL, Selwyn AP, Shook TL, et al. Paradoxical vasoconstriction induced by acetylcholine in atherosclerotic coronary arteries. N Engl J Med 1986;315:1046-51.
32. Zeiher AM, Drexler H, Wollschlager H, et al. Modulation of coronary vasomotor tone in humans. Progressive endothelial dysfunction with different early stages of coronary atherosclerosis. Circulation 1991;83:391-401.
33. Vita JA, Treasure CB, Nabel EG, et al. Coronary vasomotor response to acetylcholine relates to risk factors for coronary artery disease. Circulation 1990;81:491-7.
34. Steinberg HO, Bayazeed B, Hook G, et al. Endothelial dysfunction is associated with cholesterol levels in the high normal range in humans. Circulation 1997;96:3255-7.
35. Meredith IT, Yeung AC, Weidinger FF, et al. Role of impaired endothelium-dependent vasodilation in ischemic manifestations of coronary artery disease. Circulation 1993; 87(suppl V):V56-66.
36. Anderson TJ, Meredith IT, Yeung AC, et al. The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion. N Engl J Med 1995;332:488-93.
37. Leung W-H, Lau C-P, Wong C-K. Beneficial effect of cholesterol-lowering therapy on coronary endothelium-dependent relaxation in hypercholesterolaemic patients. Lancet 1993;341:1496-500.
38. O'Driscoll G, Green D, Taylor R. Simvastatin, an HMG-coenzyme A reductase inhibitor improves endothelial function within one month. Circulation 1997;95:1126-31.
39. Schmieder RE, Schobel HP. Is endothelial dysfunction reversible? Am J Cardiol 1995;76:117A-21A.
40. John S, Schlaich M, Langenfeld M, et al. Increased bioavailability of nitric oxide after lipid-lowering therapy in hypercholesterolaemic patients: a randomized, placebo-controlled, double-blind study. Circulation 1998;98:211-16.
41. van Boven AJ, Jukema JW, Zwinderman AH, et al. Reduction of transient myocardial ischaemia with pravastatin in addition to the conventional treatment in patients with angina pectoris. Circulation 1996;94:1503-5.
42. Andrews TC, Raby K, Barry J, et al. Effect of cholesterol reduction on myocardial ischemia in patients with coronary disease. Circulation 1997;95:324-8.
43. Buchwald H, Varco RL, Matts JP, et al. Effect of partial ileal bypass on mortality and morbidity from coronary heart disease in patients with hypercholesterolaemia. Report of the program on the surgical control of the hyperlipemias (POSCH). N Engl J Med 1990;323:946-55.
44. Brown G, Albers JJ, Fischer LD, et al. Regression of coronary artery disease as a result of intensive lipid lowering therapy in men with high levels of apolipoprotein B. N Engl J Med 1990;323:1289-98.
45. Watts GF, Lewis B, Brunt JNH, et al. Effects on coronary artery disease of lipid-lowering diet, or diet plus cholestyramine, in the St Thomas' atherosclerosis regression study (STARS). Lancet 1992;339:563-9.
46. Williams JK, Sukhova GK, Herrington DM, et al. Pravastatin has cholesterol-lowering independent effects on the artery wall of atherosclerotic monkeys. J Am Coll Cardiol 1998;31:684-91.
47. Tsuda Y, Satoh K, Kitadai M, et al. Effects of pravastatin sodium and simvastatin on plasma fibrinogen level and blood rheology in type II hyperlipoproteinaemia. Atherosclerosis 1996;112:225-33.
48. Lacoste L, Lam JYT, Hung J, et al. Hyperlipidemia and coronary disease: correction of the increased thrombogenic potential with cholesterol reduction. Circulation 1995;92: 3172-7.
49. Rosenson RS, Tangney CC. Beneficial effects of statins. Lancet 1996;348:1583.
50. Hoffman R, Brook GJ, Aviram M. Hypolipidemic drugs reduce lipoprotein susceptibility to undergo lipid peroxidation: in vitro and in vivo studies. Atherosclerosis 1992;93:105-13.
51. Chen L, Haught WH, Yang B. Preservation of endogenous antioxidant activity and inhibition of lipid peroxidation as common mechanisms of antiatheroscerotic effects of vitamin E, lovastatin and amlodipine. J Am Coll Cardiol 1997;30:569-75.
52. Corsini A, Bernini F, Quarato P, et al. Non-lipid-related effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Cardiology 1996;87:458-68.
53. Adams MR, Jessup W, Celermajer DS. Cigarette smoking is associated with increased monocyte adhesion to endothelial cells: reversibility with oral L-arginine but not vitamin C. J Am Coll Cardiol 1997;29:491-7.
54. Pech-Amsellen MA, Myara I, Storogenko M, et al. Enhanced modifications of low-density lipoproteins (LDL) by endothelial cells from smokers: a possible mechanism of smoking related atherosclerosis. Cardiovasc Res 1996;31: 975-83.
55. Zeiher AM, Schachinger V, Minners J. Long-term cigarette smoking impairs endothelium-dependent coronary arterial vasodilator function. Circulation 1995;92:1094-100.
56. Galis ZS, Asanuma K, Godin D, et al. N-acetyl-cysteine decreases the matrix-degrading capacity of macrophage-derived foam cells: new target for antioxidant therapy? Circulation 1998;97:2445-53.
57. Muhlestein JB, Anderson JL, Hammond EH, et al. Infection with Chlamydia pneumoniae accelerates the development of atherosclerosis and treatment with azithromycin prevents it in a rabbit model. Circulation 1998;97:633-6.
58. Gurfinkel E, Bozovich G, Darcoca A, et al. Randomised trial of roxithromycin in non-Q-wave coronary syndromes: ROXIS pilot study. Lancet 1997;350:404-7.